Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-headquartered private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals including in China. Financial terms were not disclosed.
The sale is part of Shiseido’s 2030 Medium-Term Strategy, under which the Japanese cosmetics group aims to improve profitability and capital efficiency. Shiseido said it wants to drive sustainable growth and strengthen its competitiveness in China by focusing management resources on areas where it has the greatest competitive advantage. The company also said the divestment allows it to concentrate on priority brands and higher-growth opportunities.
Shiseido described the subsidiary as a business that requires continued investment in product innovation and digital capabilities. It also called China a strategically important and attractive, dynamic market where the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.
SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. The company has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership ahead of the sale.
Deal structure and transition support
Under the transaction, funds managed by IDG Capital will take 95% of SLC’s equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC’s new management team will hold the remaining 5%. The deal includes SLC’s Beijing factory and production equipment.
Shiseido said it believes independent operation under IDG will support SLC’s sustainable growth and brand value. To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The company said these arrangements are intended to maintain SLC’s innovation capabilities, product quality and business continuity.
Profit recovery precedes divestment
The sale comes days after Shiseido reported a 124.3% increase in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%.
Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million) following those results. The company has framed the sale as a way to redirect resources toward priority brands and higher-growth opportunities while supporting the divested business during the transition.
